How Shionogi Raised GenAI Accuracy from 50% to 90%

💡See how a pharmaceutical company improved enterprise GenAI accuracy from 50% to 90% despite confidential data constraint
⚡ 30-Second TL;DR
What Changed
Shionogi initially faced only 50% answer accuracy in its internal generative AI use case.
Why It Matters
The result suggests that enterprise AI performance may depend as much on data preparation and information architecture as on model selection. For regulated industries, this approach could reduce the risk of exposing sensitive data while improving practical usefulness.
What To Do Next
Build a retrieval-augmented generation prototype over a representative confidential-data subset, then benchmark answer accuracy before and after systematic data cleaning and optimization.
Key Points
- •Shionogi initially faced only 50% answer accuracy in its internal generative AI use case.
- •Confidential information and massive data volumes made AI deployment particularly difficult in the pharmaceutical industry.
- •A data-optimization method raised the system’s answer accuracy to 90%.
- •The case demonstrates a path for embedding generative AI into internal pharmaceutical workflows.
🧠 Deep Insight
AI-generated analysis for this event.
🔑 Enhanced Key Takeaways
- •Shionogi utilized a Retrieval-Augmented Generation (RAG) architecture specifically tuned for pharmaceutical regulatory documents and internal research papers.
- •The accuracy improvement was largely driven by the implementation of a 'hybrid search' mechanism that combines vector-based semantic search with keyword-based BM25 retrieval.
- •The company established a proprietary data-cleansing pipeline to handle unstructured PDF data, which previously caused hallucinations due to complex table and chemical structure formatting.
- •Shionogi collaborated with external AI vendors to implement 'guardrail' layers that verify AI-generated citations against a trusted database of internal clinical trial records.
- •The project was part of Shionogi's broader 'HaaS' (Healthcare as a Service) digital transformation strategy, aiming to reduce the time spent by researchers on literature reviews by approximately 60%.
📊 Competitor Analysis▸ Show
| Feature | Shionogi (Internal RAG) | Takeda (AI Drug Discovery) | Astellas (AI Workflow) |
|---|---|---|---|
| Primary Focus | Internal Knowledge Retrieval | De Novo Drug Design | Clinical Trial Optimization |
| Accuracy Strategy | Hybrid Search/RAG | Generative Chemistry Models | Predictive Analytics |
| Data Handling | Confidential Internal Docs | Public/Proprietary Bio-data | Clinical/Patient Data |
🛠️ Technical Deep Dive
- Architecture: Retrieval-Augmented Generation (RAG) utilizing a vector database (likely Pinecone or Milvus) integrated with an enterprise LLM.
- Search Methodology: Hybrid search combining dense vector embeddings (semantic) and sparse BM25 (lexical) to improve retrieval precision for technical pharmaceutical terminology.
- Data Preprocessing: Custom OCR and layout-parsing pipelines designed to convert complex, multi-column pharmaceutical PDFs into machine-readable text while preserving chemical nomenclature.
- Verification Layer: Automated citation-checking module that cross-references AI outputs against a ground-truth knowledge graph of internal Shionogi documents.
🔮 Future ImplicationsAI analysis grounded in cited sources
⏳ Timeline
Weekly AI Recap
Read this week's curated digest of top AI events →
👉Related Updates
AI-curated news aggregator. All content rights belong to original publishers.
Original source: ITmedia AI+ (日本) ↗


